Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4082270
Max Phase: Preclinical
Molecular Formula: C15H22N3O8P
Molecular Weight: 403.33
Molecule Type: Small molecule
Associated Items:
ID: ALA4082270
Max Phase: Preclinical
Molecular Formula: C15H22N3O8P
Molecular Weight: 403.33
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: N[C@@H](CCP(=O)(O)C(O)c1ccc(N2CCOCC2)c([N+](=O)[O-])c1)C(=O)O
Standard InChI: InChI=1S/C15H22N3O8P/c16-11(14(19)20)3-8-27(24,25)15(21)10-1-2-12(13(9-10)18(22)23)17-4-6-26-7-5-17/h1-2,9,11,15,21H,3-8,16H2,(H,19,20)(H,24,25)/t11-,15?/m0/s1
Standard InChI Key: BWTDMGDNYYGBNJ-VPHXOMNUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 403.33 | Molecular Weight (Monoisotopic): 403.1145 | AlogP: 0.49 | #Rotatable Bonds: 8 |
Polar Surface Area: 176.46 | Molecular Species: ZWITTERION | HBA: 8 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 11 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 1.03 | CX Basic pKa: 9.53 | CX LogP: -2.19 | CX LogD: -5.32 |
Aromatic Rings: 1 | Heavy Atoms: 27 | QED Weighted: 0.27 | Np Likeness Score: -0.48 |
1. Selvam C, Lemasson IA, Brabet I, Oueslati N, Karaman B, Cabaye A, Tora AS, Commare B, Courtiol T, Cesarini S, McCort-Tranchepain I, Rigault D, Mony L, Bessiron T, McLean H, Leroux FR, Colobert F, Daniel H, Goupil-Lamy A, Bertrand HO, Goudet C, Pin JP, Acher FC.. (2018) Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites., 61 (5): [PMID:29397723] [10.1021/acs.jmedchem.7b01438] |
Source(1):